Terms: = Colorectal cancer AND CLTC, CLTCL2, 1213, ENSG00000141367, Q00610 AND Clinical Outcome
5 results:
1. Alpha B-crystallin C-802G polymorphism and colorectal cancer susceptibility and clinical outcome in Chinese population.
Wu X; Zheng YZ; Han B; Wang K
Sci Rep; 2018 Aug; 8(1):11731. PubMed ID: 30082880
[TBL] [Abstract] [Full Text] [Related]
2. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.
Brijwani N; Jain M; Dhandapani M; Zahed F; Mukhopadhyay P; Biswas M; Khatri D; Radhakrishna VD; Majumder B; Radhakrishnan P; Thiyagarajan S
Sci Rep; 2017 May; 7(1):1502. PubMed ID: 28473715
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.
Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
Int J Oncol; 2014 Jun; 44(6):1820-30. PubMed ID: 24715238
[TBL] [Abstract] [Full Text] [Related]
4. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract] [Full Text] [Related]
5. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.
Keogan MT; Lowe VJ; Baker ME; McDermott VG; Lyerly HK; Coleman RE
Abdom Imaging; 1997; 22(3):332-7. PubMed ID: 9107663
[TBL] [Abstract] [Full Text] [Related]
